Home | Clinical Care | Research | Training | Division Activities

Education and Training:

A.B., Harvard University, Cambridge, MA (1979)

M.D., Harvard Medical School, Massachusetts Institute of Technology Health Sciences and Technology Program, Boston, MA (1986)

Ph.D., Harvard Graduate School of Arts and Sciences, Cambridge, MA (1986)

Residency in Internal Medicine, Beth Israel Hospital, Boston, MA (1986- 88)

Hematology Fellowship, Yale University School of Medicine, New Haven, CT (1988-91)

Pamela S. Becker, MD, PhD
Professor of Medicine, Division of Hematology
University of Washington School of Medicine

Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center

Office Address:
Institute for Stem Cell and Regenerative Medicine
University of Washington Campus Box 358056
815 Mercer Street, Rm N415
Seattle, WA 98109

Voicemail only:  (206) 616-1589
Division:             (206) 543-3360
Clinical Tel:       
(206) 288-7369
Clinical Fax:      (206) 288-6356



Acute leukemia, myelodysplastic syndrome, multiple myeloma, stem cell transplant


Cell adhesion mediated chemotherapy resistance in acute myeloid leukemia and multiple myeloma, personalized leukemia therapy, hematopoietic stem cell gene transfer for Fanconi anemia


Dr. Becker is pursuing several areas of research investigation, including 1) the mechanism of adhesion mediated chemotherapy resistance in acute myeloid leukemia and 2) hematopoietic stem cell gene therapy for an inherited disorder of DNA repair, Fanconi anemia. 

1. Optimizing therapy of hematological malignancies.

    a. Environment mediated chemotherapy resistance in acute myeloid leukemia (AML) and multiple myeloma.
        We have performed extensive analysis of the interaction of acute myeloid leukemia or multiple myeloma with the bone marrow microenvironment, focusing on receptors such as VLA-4, CXCR-4 and CD44/E-selectin ligand. We test novel combinations of chemotherapy with agents that disrupt adhesion of leukemia or myeloma cells in the laboratory, with the goal of development of new clinical trials in patients.

    b. Personalized therapy of AML.
        Our goal is to better predict outcomes in AML based on in vitro high throughput drug sensitivity assays in combination with genomic information and gene expression, and develop new treatments for AML with novel targeted agents.

2. Gene therapy for inherited stem cell disorders.
        We performed the preclinical studies with a lentiviral vector in support of a gene therapy clinical trial for Fanconi (aplastic) anemia that is currently open for enrollment.


Becker PS
, Li Z, Potselueva T, Madri JA, Newburger PE. Berliner N.  Laminin promotes differentiation of NB4 promyelocytic leukemia cells with all-trans retinoic acid. Blood 88:261-267, 1996.

Rossi H, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS. GM-CSF priming with successive concomitant therapy with low dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 16:301-305, 2002.

Gold J, Valinski, HM, Hanks AN, Ballen KK, Hsieh CC, Becker PS. Adhesion receptor expression by CD34+ cells from peripheral blood or bone marrow grafts: correlation with time to engraftment.  Exp. Hematol. 34(5):680-7, 2006.

Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR.  Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.  Blood 113:866-874, 2009.

Rosenbloom B, Becker P, Weinreb N.  Multiple myeloma and Gaucher genes.  Genet. Med., 11:134, 2009.

Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, Chien S, Adair J, Kohn DB, Wagner JE, Shimamura A and Kiem H-P. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Therapy 17:1244-1252, 2010.

Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukemia. Brit. J. Haematol. 155:182-189, 2011.

Miller CP, Rattray K, Zhang Y, Wood BL, Burwick N, Chien S, Bensinger WI, Blau CA, Becker PS. Evaluating surface erythropoietin receptor in multiple myeloma. Leukemia 26:1883-6, 2012.

Adair J, Zhao X, Chien S, Fang M, Wohlfahrt ME, Trobridge G, Taylor J, Beard BC, Kiem H-P, Becker PS. Conditioning regimens for gene transfer for Fanconi Anemia. J Mol Med 90:1283-94, 2012

Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH. Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without G-CSF as salvage therapies for acute myeloid leukemia (AML). Haematologica 98:114-8, 2013.

Roshal M, Chien S, Othus M, Wood B, Fang M, Appelbaum FR, Estey EH, Papayannopoulou T, and Becker PS. The proportion of CD34+CD38low or neg myeloblasts, but not side population (SP) frequency, predicts initial response to induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leukemia 27:728-31, 2013.

Bensinger WI, Green DJ, Burwick N, Becker PS. A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. Bone Marrow Transplant. 2014 Apr;49(4):492-5.

Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler V, Appelbaum FR, Becker PS. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer Journal. 5:e302, 2015.

Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL,, Estey EH. G-CSF priming, clofarabine, and high doce cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. Am J Hematol. 90(4):295-300, 2015.

Becker PS, Gooley TA, Green DJ, Burwick N, Kim TY, Kojouri K, Inoue Y, Moore DJ, Nelli E, Denni T, Bensinger WI. A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone (BCDD) for newly diagnosed multiple myeloma. Blood Cancer Journal. 6:e422; 2016.